Department of Cardiology, University Medical Centre Groningen, University of Groningen, PO Box 30 001, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.
Ann Med. 2011 Feb;43(1):60-8. doi: 10.3109/07853890.2010.538080. Epub 2010 Dec 28.
galectin-3 is an emerging biomarker which has been studied in relatively small heart failure (HF) cohorts with predominantly systolic HF. We studied the prognostic value of base-line galectin-3 in a large HF cohort, with preserved and reduced left ventricular ejection fraction (LVEF), and compared this to other biomarkers.
we studied 592 HF patients who had been hospitalized for HF and were followed for 18 months. The primary end-point was a composite of all-cause mortality and HF hospitalization.
a doubling of galectin-3 levels was associated with a hazard ratio (HR) of 1.97 (1.62-2.42) for the primary outcome (P < 0.001). After correction for age, gender, BNP, eGFR, and diabetes the HR was 1.38 (1.07-1.78; P = 0.015). Galectin-3 levels were correlated with higher IL-6 and CRP levels (P < 0.002). Changes of galectin-3 levels after 6 months did not add prognostic information to the base-line value (n = 291); however, combining plasma galectin-3 and BNP levels increased prognostic value over either biomarker alone (ROC analysis, P < 0.05). The predictive value of galectin-3 was stronger in patients with preserved LVEF (n = 114) compared to patients with reduced LVEF (P < 0.001).
galectin-3 is an independent marker for outcome in HF and appears to be particularly useful in HF patients with preserved LVEF.
半乳糖凝集素-3 是一种新兴的生物标志物，已在以收缩性心力衰竭为主的相对较小的心力衰竭（HF）队列中进行了研究。我们研究了基线半乳糖凝集素-3在大型 HF 队列中的预后价值，该队列的左心室射血分数（LVEF）保留和降低，并将其与其他生物标志物进行了比较。
我们研究了 592 名因 HF 住院并随访 18 个月的 HF 患者。主要终点是全因死亡率和 HF 住院的复合终点。
半乳糖凝集素-3 水平加倍与主要结局（所有原因死亡和 HF 住院）的风险比（HR）为 1.97（1.62-2.42）（P < 0.001）。校正年龄、性别、BNP、eGFR 和糖尿病后，HR 为 1.38（1.07-1.78；P = 0.015）。半乳糖凝集素-3 水平与更高的 IL-6 和 CRP 水平相关（P < 0.002）。6 个月后半乳糖凝集素-3 水平的变化并未增加基线值的预后信息（n = 291）；然而，将血浆半乳糖凝集素-3 和 BNP 水平相结合可提高单个生物标志物的预后价值（ROC 分析，P < 0.05）。与 LVEF 降低的患者相比，LVEF 保留的患者中半乳糖凝集素-3 的预测价值更强（P < 0.001）。
半乳糖凝集素-3 是 HF 患者预后的独立标志物，在 LVEF 保留的 HF 患者中似乎特别有用。
